Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-08-04 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Lynparza in the EU for early breast cancer, including clinical trial results, regulatory milestones, and company collaboration details. The document is not an annual or quarterly financial report, nor is it a transcript, proxy, or governance document. It is a regulatory filing providing material information about a significant corporate event (drug approval and related financial milestone). The document length is substantial (15,000 characters), and it is a formal SEC filing type 6-K, which is used for current reports by foreign issuers. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-04 English
Lynparza approved in EU for early breast cancer
Regulatory Filings Classification · 95% confidence The document is a press release dated August 4, 2022, originating from AstraZeneca PLC, identified by the RNS Number 9049U. The content announces a regulatory event: the approval of Lynparza in the European Union (EU) for a specific cancer treatment. It details the basis for the approval (OlympiA Phase III trial results), provides quotes from executives and researchers, and mentions a resulting financial milestone payment ($75m from MSD). This type of announcement, which communicates a significant regulatory or clinical development outcome, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement of a regulatory event that doesn't fit other specific categories like M&A (TAR) or Director's Dealing (DIRS). Since it is a specific announcement of a regulatory approval and subsequent financial impact, and it is not a full financial report (10-K, IR) or a transcript (CT), the most appropriate general category for a significant, non-periodic regulatory update that is not a specific financial filing form is RNS, as it is a general regulatory news service announcement.
2022-08-04 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a director's shareholding transaction. It details the vesting of shares to a Chief Financial Officer and the related transaction information. The content focuses on insider share transactions by a person discharging managerial responsibilities (PDMR). There is no financial performance data, earnings information, or report publication announcement. The document is a notification of a director's dealing in shares, consistent with insider trading disclosures. Therefore, the appropriate classification is Director's Dealing (DIRS). The document length and detail support a high confidence in this classification.
2022-08-01 English
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is an official announcement disseminated via RNS (Regulatory News Service) from AstraZeneca PLC. It details a transaction involving a Person Discharging Managerial Responsibilities (PDMR), specifically the vesting of American Depositary Shares (ADSs) to the Chief Financial Officer, Dr. Aradhana Sarin. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of 'Director's Dealing'. The presence of the RNS Number, the date, and the structured table detailing the transaction (price, volume, date) confirms this is a regulatory disclosure of insider trading activity, matching the 'DIRS' code.
2022-08-01 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date (31 July 2022) and provides information about the issued share capital and voting rights. The document is relatively short (3172 characters) and primarily serves as a notification of voting rights rather than a detailed financial report or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. The document is an official regulatory announcement related to shareholder voting rights and capital structure but does not report voting results or changes in share ownership thresholds. Therefore, it best fits the category of Regulatory Filings (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-01 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on a director's shareholding transaction, specifically the vesting of American Depositary Shares to the Chief Financial Officer. It includes detailed information about the transaction, such as the number of shares, price, and date, and is made in accordance with EU Market Abuse Regulation requirements. This type of filing is a notification of personal share transactions by a company director, which fits the definition of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a full financial report but a specific insider transaction report.
2022-08-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.